Latest Maze news - BleepingComputer
The infamous Maze ransomware gang announced today that they have officially closed down their ransomware operation and will no longer be leaking new companies' data on their site.
Frankie Beverly, lead singer and founder of Maze, dead at 77 - CNN
Sep 11, 2024 · Frankie Beverly, who with his band Maze gave the world an anthem that will forever be tied to cookouts and good times, died on Tuesday, his family announced. He was 77.
FTC Seeks to Block Sanofi’s Acquisition of Rare Disease Drug that ...
Dec 11, 2023 · Sanofi is a monopoly supplier of Food and Drug Administration (FDA) approved drugs to treat the disease. According to the FTC’s complaint, Maze’s Phase 2-ready developmental drug—a glycogen synthase 1 inhibitor called MZE001—threatens to undermine this monopoly as the first oral medication available for Pompe disease patients.
Frankie Beverly dead: 'Before I Let Go' singer, Maze founder was 77
Sep 11, 2024 · Frankie Beverly, the "Before I Let Go" hitmaker with his band Maze, has died. He was 77. His death on Tuesday was announced by his family on the official Frankie Beverly and …
Kidney disease drugmaker Maze files for IPO - BioPharma Dive
Jan 8, 2025 · Maze is the second biotech to seek a Nasdaq IPO in recent weeks. China-based drugmaker Ascentage Pharma on Dec. 27 filed a plan to list its American depositary shares.
Maze lands new partner for Pompe drug, after Sanofi pact came …
May 10, 2024 · Biotechnology startup Maze Therapeutics has licensed a Pompe disease drug to Shionogi, five months after a challenge from the Federal Trade Commission caused Sanofi to …
Maze CEO ‘disappointed’ in Sanofi decision to end partnership
Dec 12, 2023 · W hen Sanofi terminated its partnership with Maze Therapeutics this week to develop an experimental drug for Pompe disease, Maze CEO Jason Coloma did not learn the news in a conference call...
FTC, in unusual move, leads Sanofi to terminate a drug research deal
Dec 12, 2023 · Sanofi terminated a licensing deal with biotechnology company Maze Therapeutics Monday after the Federal Trade Commission filed a lawsuit alleging that the collaboration was designed to extend the French drugmaker’s monopoly in treating a rare disorder known as Pompe disease.
news, press, & publications - Maze Therapeutics
Nov 13, 2024 · Maze Therapeutics Initiates Phase 1 First-in-Human Trial Evaluating MZE782 as a Potential Treatment for Chronic Kidney Disease
Sanofi strikes a $150M deal for Maze’s Pompe disease drug
May 1, 2023 · In a deal announced Monday, Sanofi will acquire rights to develop and commercialize Maze’s drug candidate MZE001, which is slated to begin a Phase 2 study later this year. Maze has raised $381 million in private financing since launching in 2019.